Triptan Therapy for Acute Episodic Migraine
For adults with episodic migraine without cardiovascular contraindications, start with combination therapy of a triptan plus an NSAID (or acetaminophen if NSAIDs are contraindicated) rather than triptan monotherapy, as this provides superior pain relief and sustained freedom from pain. 1
Treatment Algorithm
First-Line Approach
- Add a triptan to an NSAID for moderate to severe migraine if NSAIDs alone have failed 1
- Add a triptan to acetaminophen if NSAIDs are contraindicated or not tolerated 1
- Begin treatment as soon as possible after migraine onset to maximize efficacy 1
Triptan Selection
Any of the following triptans are appropriate - selection should be based on patient preference regarding route of administration and cost 1:
- Almotriptan
- Eletriptan
- Frovatriptan
- Naratriptan
- Rizatriptan
- Sumatriptan
- Zolmitriptan
Among oral formulations, research suggests eletriptan 40 mg has the highest efficacy (30.9% pain-free at 2 hours after eliminating placebo effect), while naratriptan 2.5 mg has the lowest (10.3% pain-free at 2 hours) 2. However, the 2025 ACP guideline emphasizes that choice within the triptan class should prioritize individualized factors rather than specific agent superiority 1.
Route of Administration Considerations
For severe nausea or vomiting: Use a non-oral triptan formulation plus an antiemetic 1
Efficacy by route 2:
- Subcutaneous administration provides significantly higher efficacy than oral (e.g., subcutaneous sumatriptan 6 mg has fastest onset, with 90.6% of 2-hour pain-free patients maintaining relief at 4 hours)
- Nasal spray efficacy is comparable to oral administration
- Oral formulations remain preferred by most patients based on convenience 1
Specific Dosing Examples
While the guideline does not mandate specific doses, research provides the following effective regimens:
- Sumatriptan: 50-100 mg orally (50 mg effective for most patients) 3; 6 mg subcutaneously 2; 5-20 mg nasal spray (dose-dependent efficacy increase) 2
- Rizatriptan: 5-10 mg orally (dose-response relationship demonstrated) 4
- Eletriptan: 40 mg orally 2
- Frovatriptan: 2.5 mg orally (longest half-life at ~26 hours, may reduce recurrence) 5
Critical Safety Considerations
Medication overuse headache threshold: Limit triptan use to <10 days per month (stricter than the ≥15 days/month threshold for NSAIDs) 1
Absolute contraindications (patient must be screened):
- Cardiovascular disease
- Uncontrolled hypertension
- Peripheral vascular disease
- Hemiplegic or basilar migraine
- Recent stroke or TIA
Do NOT use opioids or butalbital for acute migraine treatment 1
Evidence Strength
The recommendation for combination therapy over monotherapy is based on high-certainty evidence showing combination therapy (triptan + NSAID) results in 1:
- 180 more patients per 1000 achieving sustained pain relief up to 48 hours
- 70 more patients per 1000 achieving sustained pain freedom up to 48 hours
- 160 fewer patients per 1000 requiring rescue medication
The combination of triptan + acetaminophen has moderate-certainty evidence for pain freedom outcomes but low-certainty evidence for overall comparative effectiveness 1.
When Combination Therapy Fails
If combination therapy provides inadequate response, consider second-line options in this order 1:
- CGRP antagonists (gepants: rimegepant, ubrogepant, zavegepant)
- Ergot alkaloid (dihydroergotamine)
- Lasmiditan (ditan) - reserve for patients who fail all other treatments
Additional Management Points
- If migraines occur frequently despite acute treatment, add preventive medications 1
- Patients who fail one triptan may respond to another within the class 1
- Prescribe less costly options when clinically equivalent (generic triptans cost ~$500 annually vs. $5994-6668 for newer agents) 1
- For childbearing-age patients, discuss pregnancy/lactation risks before prescribing 1